AR124451A1 - DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES - Google Patents
DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO Y SU USO EN EL TRATAMIENTO DE ENFERMEDADESInfo
- Publication number
- AR124451A1 AR124451A1 ARP210103599A ARP210103599A AR124451A1 AR 124451 A1 AR124451 A1 AR 124451A1 AR P210103599 A ARP210103599 A AR P210103599A AR P210103599 A ARP210103599 A AR P210103599A AR 124451 A1 AR124451 A1 AR 124451A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- disease
- halo
- cycloalkyl
- alkoxy
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/444—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring heteroatom, e.g. amrinone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Rheumatology (AREA)
- Pain & Pain Management (AREA)
- Immunology (AREA)
- Ophthalmology & Optometry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Abstract
Esta divulgación se relaciona con derivados de imidazo[1,2-a]piridinilo de fórmula (1), o sales farmacéuticamente aceptables de estos, donde todas las variables son como se definen en la memoria descriptiva, capaces de modular la actividad de IRAK4. La divulgación proporciona además métodos para su preparación, para su uso médico, en particular para su uso en el tratamiento y manejo de enfermedades o trastornos que incluyen enfermedad inflamatoria, enfermedad autoinmune, cáncer, enfermedad cardiovascular, una enfermedad del sistema nervioso central, enfermedad de la piel, una enfermedad y afección oftálmica y una enfermedad de los huesos. Reivindicación 1: Un compuesto representado por la fórmula (1), o una sal farmacéuticamente aceptable de este, donde: X es CH, CF o N; Y es CH o N; Z es el anillo A o -CH₂-anillo A-*, donde ⁻⁻⁻⁻* indica el punto de conexión a R¹; el anillo A es un resto seleccionado del grupo de fórmulas (2), donde n es 1 ó 2; W está ausente, CH₂ u O, y ⁻⁻⁻⁻* indica el punto de conexión con R¹; R¹ es H, -CN, alcoxi C₁₋₃ o alquilo C₁₋₃ opcionalmente sustituido con 1 a 3 sustituyentes seleccionados independientemente de halo y alcoxi C₁₋₃; R² es cicloalquilo C₃₋₆ o alquilo C₁₋₄, donde el cicloalquilo C₃₋₆ o alquilo C₁₋₄ está opcionalmente sustituido con 1 a 3 halo; y R³, R⁴, R⁵, R⁶ y R⁷ se seleccionan cada uno independientemente de H, halo, CN, alquilo C₁₋₄, haloalquilo C₁₋₄, alcoxi C₁₋₄ y alcoxi C₁₋₄alquilo C₁₋₄, o dos cualesquiera de R³, R⁴, R⁵, R⁶ y R⁷ junto con los átomos de carbono a los que están unidos forman un cicloalquilo C₃₋₆ o un heterociclilo de 4 a 6 miembros que contiene uno o dos heteroátomos seleccionados independientemente de O, N y S; y R⁸ es H o halo.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202063128964P | 2020-12-22 | 2020-12-22 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR124451A1 true AR124451A1 (es) | 2023-03-29 |
Family
ID=80050991
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP210103599A AR124451A1 (es) | 2020-12-22 | 2021-12-21 | DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES |
Country Status (15)
| Country | Link |
|---|---|
| US (1) | US20240116922A1 (es) |
| EP (1) | EP4267576A1 (es) |
| JP (1) | JP2024501282A (es) |
| KR (1) | KR20230134500A (es) |
| CN (1) | CN116867781A (es) |
| AR (1) | AR124451A1 (es) |
| AU (1) | AU2021409546A1 (es) |
| CA (1) | CA3203129A1 (es) |
| CO (1) | CO2023009316A2 (es) |
| IL (1) | IL303966A (es) |
| JO (1) | JOP20230148A1 (es) |
| MX (1) | MX2023007511A (es) |
| TW (1) | TW202332435A (es) |
| UY (1) | UY39584A (es) |
| WO (1) | WO2022140425A1 (es) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| UY39844A (es) * | 2021-07-07 | 2023-01-31 | Biogen Ma Inc | Compuestos para la degradación selectiva de las proteínas irak4 |
| PE20242100A1 (es) * | 2022-02-14 | 2024-10-28 | Astrazeneca Ab | Inhibidores de irak4 |
Family Cites Families (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2514733A1 (en) | 2003-02-28 | 2004-09-16 | Transform Pharmaceuticals, Inc. | Pharmaceutical co-crystal compositions of drugs such as carbamazepine, celecoxib, olanzapine, itraconazole, topiramate, modafinil, 5-fluorouracil, hydrochlorothiazide, acetaminophen, aspirin, flurbiprofen, phenytoin and ibuprofen |
| JP7576552B2 (ja) | 2019-01-18 | 2024-10-31 | バイオジェン・エムエイ・インコーポレイテッド | イミダゾ［１，２－ａ］ピリジニル誘導体及び疾患の処置におけるその使用 |
| EP3990454A1 (en) * | 2019-06-27 | 2022-05-04 | Biogen MA Inc. | Imidazo[1,2-a]pyridinyl derivatives and their use in the treatment of disease |
| UY38765A (es) * | 2019-06-27 | 2021-01-29 | Biogen Ma Inc | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades |
-
2021
- 2021-12-21 AR ARP210103599A patent/AR124451A1/es not_active Application Discontinuation
- 2021-12-21 EP EP21848378.2A patent/EP4267576A1/en active Pending
- 2021-12-21 JP JP2023538705A patent/JP2024501282A/ja active Pending
- 2021-12-21 AU AU2021409546A patent/AU2021409546A1/en not_active Abandoned
- 2021-12-21 CN CN202180094021.2A patent/CN116867781A/zh active Pending
- 2021-12-21 US US18/269,073 patent/US20240116922A1/en active Pending
- 2021-12-21 IL IL303966A patent/IL303966A/en unknown
- 2021-12-21 KR KR1020237025045A patent/KR20230134500A/ko active Pending
- 2021-12-21 MX MX2023007511A patent/MX2023007511A/es unknown
- 2021-12-21 UY UY0001039584A patent/UY39584A/es unknown
- 2021-12-21 WO PCT/US2021/064666 patent/WO2022140425A1/en not_active Ceased
- 2021-12-21 TW TW110148009A patent/TW202332435A/zh unknown
- 2021-12-21 CA CA3203129A patent/CA3203129A1/en active Pending
-
2023
- 2023-06-21 JO JOJO/P/2023/0148A patent/JOP20230148A1/ar unknown
- 2023-07-13 CO CONC2023/0009316A patent/CO2023009316A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| EP4267576A1 (en) | 2023-11-01 |
| CO2023009316A2 (es) | 2023-09-29 |
| IL303966A (en) | 2023-08-01 |
| JOP20230148A1 (ar) | 2023-06-21 |
| CA3203129A1 (en) | 2022-06-30 |
| AU2021409546A1 (en) | 2023-07-06 |
| WO2022140425A1 (en) | 2022-06-30 |
| MX2023007511A (es) | 2023-09-08 |
| UY39584A (es) | 2022-07-29 |
| CN116867781A (zh) | 2023-10-10 |
| KR20230134500A (ko) | 2023-09-21 |
| US20240116922A1 (en) | 2024-04-11 |
| AU2021409546A9 (en) | 2025-04-10 |
| JP2024501282A (ja) | 2024-01-11 |
| TW202332435A (zh) | 2023-08-16 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR119234A1 (es) | Derivados de imidazo[1,2-a]piridinilo y su uso en el tratamiento de enfermedades | |
| AR119244A1 (es) | Derivados de 2h-indazol y su uso en el tratamiento de enfermedades | |
| AR117490A1 (es) | Inhibidores de kif18a | |
| AR121078A1 (es) | Derivados de arilamida con actividad antitumoral | |
| AR112834A1 (es) | Derivados de rapamicina | |
| AR110139A1 (es) | COMPUESTOS MONO Y ESPIROCÍCLICOS QUE CONTIENEN CICLOBUTANO Y AZETIDINA COMO INHIBIDORES DE LA INTEGRINA aV | |
| AR087760A1 (es) | Heterociclilaminas como inhibidores de pi3k | |
| AR118768A1 (es) | Derivados de pirimidina como inhibidores de las cinasas jak | |
| AR049300A1 (es) | Compuestos triciclicos antagonistas de mglur1 como agentes terapeuticos | |
| AR111295A1 (es) | Composiciones de pirrolopirrol como activadores de piruvato quinasa (pkr) | |
| AR126351A1 (es) | Compuestos y sus sales inhibidores del inflamasoma nlrp3 | |
| AR089285A1 (es) | Derivados de betulina | |
| AR119322A1 (es) | Compuestos derivados de 1h-pirido[1,2-a]pirazina como inhibidores de magl | |
| AR107714A1 (es) | Derivados de pirazolo[1,5-a]pirazin-4-ilo | |
| AR124451A1 (es) | DERIVADOS DE IMIDAZO[1,2-a]PIRIDINILO Y SU USO EN EL TRATAMIENTO DE ENFERMEDADES | |
| AR102213A1 (es) | Inhibidores de la biosíntesis de sulfato de heparano para el tratamiento de enfermedades | |
| AR112216A1 (es) | Derivados de azaquinolina | |
| AR121269A1 (es) | Inhibidores de la ectonucleótido pirofosfatasa / fosfodiesterasa 1 (enpp1) y métodos de uso de los mismos | |
| AR091027A1 (es) | Analogos de benzomorfano y el usos de estos | |
| AR120246A1 (es) | Aminas heteroaril-bifenilas para el tratamiento de las enfermedades por pd-l1 | |
| AR123078A1 (es) | Medicamentos antiplaquetarios y usos de estos | |
| AR117900A1 (es) | Pirazolopiridinas y triazolopiridinas como inhibidores de a2a / a2b | |
| AR120869A1 (es) | Ácidos 1,5-difenilpirazolil-3-oxialquílicos y ácidos 1-fenil-5-tienilpirazolil-3-oxialquílicos y su uso para el combate del crecimiento de plantas no deseado | |
| AR100714A1 (es) | Derivados de alquilo y arilo de compuestos de 1-oxa-4,9-diazaespiro undecano que tienen actividad multimodal contra el dolor | |
| BRPI1016232A2 (pt) | Composto de carbinol, medicamento, regulador de lxr, composição farmacêutica, método para prevenir e/ou tratar doenças, e, uso do composto de carbinol |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FA | Abandonment or withdrawal |